These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29792354)

  • 41. The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery.
    El Bairi K; Atanasov AG; Amrani M; Afqir S
    Biomed Pharmacother; 2019 Jan; 109():2492-2498. PubMed ID: 30551510
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transforming cancer drug discovery with Big Data and AI.
    Workman P; Antolin AA; Al-Lazikani B
    Expert Opin Drug Discov; 2019 Nov; 14(11):1089-1095. PubMed ID: 31284790
    [No Abstract]   [Full Text] [Related]  

  • 43. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of the Histoculture Drug Response Assay (HDRA).
    Hoffman RM; Vescio RA
    Methods Mol Biol; 2018; 1760():39-48. PubMed ID: 29572792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
    Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
    Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
    [No Abstract]   [Full Text] [Related]  

  • 46. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Future of Precision Oncology for the Treatment of Solid Tumors.
    Klute KA
    Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
    [No Abstract]   [Full Text] [Related]  

  • 48. [The breakthrough of personalized medicine, new hopes and new challenges].
    Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
    Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-centric trials for therapeutic development in precision oncology.
    Biankin AV; Piantadosi S; Hollingsworth SJ
    Nature; 2015 Oct; 526(7573):361-70. PubMed ID: 26469047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

  • 51. Letter from the Editor: stratified medicine.
    Reichert JM
    MAbs; 2010; 2(2):107. PubMed ID: 21358857
    [No Abstract]   [Full Text] [Related]  

  • 52. Nucleoside analogs: ready to enter the era of precision medicine?
    Ciccolini J; Serdjebi C; Le Thi Thu H; Lacarelle B; Milano G; Fanciullino R
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):865-77. PubMed ID: 27218825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer stem cell targeted therapy: progress amid controversies.
    Wang T; Shigdar S; Gantier MP; Hou Y; Wang L; Li Y; Shamaileh HA; Yin W; Zhou SF; Zhao X; Duan W
    Oncotarget; 2015 Dec; 6(42):44191-206. PubMed ID: 26496035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Precision Medicine.
    Khatri VP; Petrelli NJ
    Surg Oncol Clin N Am; 2020 Jan; 29(1):xv-xvi. PubMed ID: 31757318
    [No Abstract]   [Full Text] [Related]  

  • 56. Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents.
    Ajani OO; Nlebemuo MT; Adekoya JA; Ogunniran KO; Siyanbola TO; Ajanaku CO
    Acta Pharm; 2019 Jun; 69(2):177-196. PubMed ID: 31259731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
    Beer PA; Cooke SL; Chang DK; Biankin AV
    Ann Oncol; 2019 Nov; 30(11):1691-1694. PubMed ID: 31665210
    [No Abstract]   [Full Text] [Related]  

  • 58. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.
    Morgan MM; Johnson BP; Livingston MK; Schuler LA; Alarid ET; Sung KE; Beebe DJ
    Pharmacol Ther; 2016 Sep; 165():79-92. PubMed ID: 27218886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?
    Gyawali B
    J Natl Compr Canc Netw; 2017 Jul; 15(7):859-862. PubMed ID: 28687572
    [No Abstract]   [Full Text] [Related]  

  • 60. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.
    Somarelli JA; Roghani RS; Moghaddam AS; Thomas BC; Rupprecht G; Ware KE; Altunel E; Mantyh JB; Kim SY; McCall SJ; Shen X; Mantyh CR; Hsu DS
    Mol Cancer Ther; 2020 Dec; 19(12):2516-2527. PubMed ID: 33158998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.